This page shows anti-doping rule violation data we have registered for Oxandrolone.
Oxandrolone ranks #14 globally among prohibited substances, with 303 registered cases (2.1% of all violations) among all sports tracked by the Anti-Doping Database, which contains 14,670 verified cases. Russia leads with 38 cases, while Bodybuilding is the most affected sport (71 cases).
Bodybuilding has the most recorded cases of Oxandrolone violations globally, with 71 registered cases — 0% of all 303 verified cases.
Russia leads in Oxandrolone violations globally, with 38 registered cases — 12.5% of all 303 verified cases.
Oxandrolone ranks #14 of 358 prohibited substances in the Anti-Doping Database.
This ranking covers only prohibited substances with verified case records in the Anti-Doping Database. Procedural violations (whereabouts failures, refusals to test, etc.) are excluded.
The average suspension for Oxandrolone violations is 44.9 months, longer than the global average of 30.1 months.
Oxandrolone is a man-made anabolic steroid. Because it is anabolic it also promotes the growth of muscle tissue.
In medicine, this medication has been classified as a androgenic hormones. It works by increasing the amount of protein made by the body. This protein is used to build more muscle and increase body weight.
The steroid is used with a diet program to cause weight gain in people who have lost too much weight due to surgery, injury, chronic (long-lasting) infections, trauma, or who are underweight for unknown reasons.
Oxandrolone is also used to treat bone pain in people with osteoporosis and to prevent certain side effects in people who take corticosteroids for a long time.
Food and Drug Administration (FDA) in the USA decided to pull the medication from the market in the USA. FDA believes that the potential problems associated with oxandrolone tablets are sufficiently serious that the drug should be removed from the market.
Oxandrin was approved by the FDA in 1964 to relieve bone pain in osteoporosis. However, in 1984 an FDA advisory committee concluded there was no evidence of efficacy for tablets.
Oxandrolone and similar medications may cause damage to the liver or spleen and liver cell tumors - sometimes fatal. Blood lipid changes that are known to be associated with increased risk of atherosclerosis.
Using this product include the risks associated with cholestatic hepatitis, hypercalcemia in patients with breast cancer, and increased risk for the development of prostatic hypertrophy and prostatic carcinoma in geriatric patients.
If you use this data, please credit The Anti-Doping Database
Used by journalists, sport lawyers, NADOs and researchers worldwide for proactive strategy — not just post-case research.
As a subscriber you get instant access to verified, structured anti-doping case data — from hours of research to seconds:
The Anti-Doping Database currently contains 14,670 verified anti-doping rule violations across all sports and all countries, and is updated regularly.